Published in

Karger Publishers, Journal of Vascular Research, 5(46), p. 435-446, 2009

DOI: 10.1159/000197866

Links

Tools

Export citation

Search in Google Scholar

Salivary Gland Homogenates of <i>Lutzomyia longipalpis</i> and Its Vasodilatory Peptide Maxadilan Cause Plasma Leakage via PAC1 Receptor Activation

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

<i>Objectives:</i> Experiments were designed to determine if salivary gland homogenates (SGH) of the sand fly <i>Lutzomyia longipalpis</i>, the vasodilatory peptides maxadilan and pituitary adenylate cyclase-activating peptide (PACAP-38) may cause plasma leakage and to what extent these effects could be due to PAC1 receptor stimulation. <i>Methods:</i> Using FITC-dextran as a plasma marker, intravital microscopy of the hamster cheek pouch (HCP) and a digital camera were used to assess arteriolar diameter and fluorescence of a selected area (5 mm<sup>2</sup>) representative of the HCP microcirculation. <i>Results:</i> Cheek pouches prepared for intravital microscopy and exposed to topical application of SGH, maxadilan or PACAP-38 developed maximal dilation of arterioles in the range of 20–60 μm within 10 min, and this effect lasted for 30–90 min. The increase in fluorescence intensity induced by each of these compounds was due to plasma leakage from postcapillary venules. The mutant peptide of maxadilan (M-65), a PAC1 receptor antagonist, inhibited both dilation and plasma leakage induced by SGH or maxadilan. Plasma leakage induced by SGH was modestly inhibited by the bradykinin B<sub>2</sub> receptor antagonist HOE-140, but not by the antihistamine mepyramine or the nitric oxide synthase inhibitor <i>L</i>-NA. <i>Conclusions:</i> SGH of <i>L. longipalpis</i> and its vasodilatory peptide maxadilan caused long-lasting arteriolar dilation and plasma leakage in the cheek pouch via PAC1 receptor activation.